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Background: Present study provides clinical evidence of existence of a functional loop involving miR-21 and let-7a
as potential regulators of aberrant STAT3 signaling recently reported by our group in an experimental setup
(Shishodia et al. BMC Cancer 2014, 14:996). The study is now extended to a set of cervical tissues that represent
natural history of human papillomavirus (HPV)-induced tumorigenic transformation.
Materials and methods: Cervical tissues from histopathologically-confirmed pre-cancer (23) and cancer lesions (56)
along with the normal control tissues (23) were examined for their HPV infection status, expression level of miR-21
& let-7a and STAT3 & pSTAT3 (Y705) by PCR-based genotyping, quantitative real-time PCR and immunoblotting.
Results: Analysis of cancer tissues revealed an elevated miR-21 and reduced let-7a expression that correspond to
the level of STAT3 signaling. While miR-21 showed direct association, let-7a expression was inversely related to
STAT3 expression and its activation. In contrast, a similar reciprocal expression kinetics was absent in LSIL and HSIL
tissues which overexpressed let-7a. miR-21 was found differentially overexpressed in HPV16-positive lesions with a
higher oncoprotein E6 level. Overexpression of miR-21 was accompanied by elevated level of other STAT3-regulated
gene products MMP-2 and MMP-9. Enhanced miR-21 was found associated with decreased level of STAT3 negative
regulator PTEN and negative regulator of MMPs, TIMP-3.
Conclusion: Overall, our study suggests that the microRNAs, miR-21 and let-7a function as clinically relevant integral
components of STAT3 signaling and are responsible for maintaining activated state of STAT3 in HPV-infected cells
during cervical carcinogenesis.
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Recent observations from our laboratory [1, 2] and others
[3, 4] indicate involvement of an aberrantly expressed and
constitutively active STAT3 in cervical carcinogenesis and
its level increases with progression of disease in HPV16-
infected cervical lesions. Aberrant activation of STAT3
has been strongly implicated in epithelial transformation
[5] and plays a functional role in HPV16-induced cervical
carcinogenesis [6]. Aberrant STAT3 signaling has therefore* Correspondence: alokchandrab@yahoo.com
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© 2015 Shishodia et al.been emerging as a key cellular event that links chronic
inflammation to cancer [7] and frequently reported in ma-
jority of cancers [8, 9]. However, the cellular events re-
sponsible for constitutively active STAT3 signaling and
modulation of its downstream cellular effects remained a
poorly-defined area and demanded better understanding
for its effective therapeutic targeting. Although there are a
number of positive and negative protein regulators that
control expression and activity of STAT3, recent studies
implicate involvement of microRNAs in controlling STAT
proteins/activity and the downstream targets of STAT3 as
well [10]. Considering the broad spectrum of these down-
stream targets, miRNAs are increasingly gaining attention
as a class of prime regulators or ‘tuners’ of biological
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acting with aberrant STAT3 signaling in general and cer-
vical carcinogenesis in particular is currently lacking.
Altered expression of multiple miRNAs has been re-
ported in HPV-positive cervical cancer cells [11–14].
Among oncogenically-relevant miRNAs that could po-
tentially impact STAT3 signaling, we examined involve-
ment of miR-21 and let-7a experimentally [15]. The
upstream enhancer of miR-21 gene was found to contain
two STAT3 binding sites that are strictly conserved.
Interestingly, miR-21 is located in the fragile site FRA17B
region, which is also one of the HPV16 integration loci
at 17q23.2 [16]. miR-21 has been found to control apop-
tosis, cell proliferation, and cell migration in breast,
colorectal, and other cancers [17–20]. Aberrantly ex-
pressed miR-21 has recently been proposed in cervical
carcinogenesis as well [21–25]. Similarly, assessment of
STAT3 transcript as miR target revealed let-7a as an im-
portant regulator of STAT3 level [26]. Let-7a is often de-
creased in cancer cells through chromosomal deletion
[27, 28]. Ectopic Let-7a expression indirectly represses
STAT3 transcription through its binding to the 3’-UTR
of IL-6, which is a major STAT3-inducing, carcinogenically-
relevant cytokine [7]. Moreover, STAT3 has been re-
ported as direct cellular target of let-7a [26]. Our
observations strongly indicated a functional implication
of altering levels of either miR-21, let-7a or STAT3 sig-
naling on each other in cervical cancer cell lines and the
loop was found controlled by HPV oncoprotein E6 in
in vitro studies [15]. However, the clinical correlates of
such an operational loop in tumor tissues are yet to be
established.
Furthermore, STAT3 which is activated primarily
through phosphorylation at Tyr705 residue [29] controls
MMP expression and activity, and thus plays a pivotal
role in invasion and metastasis during cervical cancer
[30, 31]. STAT3 upregulates activity of both promoters
of MMPs and tissue inhibitors of MMPs (TIMPs) which
are considered as major molecular mediators responsible
for malignant switching of tumors [32–35]. However,
how these events are mechanistically regulated and in-
volvement, if any, of microRNA in these events is poorly
understood.
In view of the above, we evaluated the expression level
of miR-21 and let-7a and examined their association
with level of STAT3 and active STAT3 (pSTAT3 Tyr705)
in different grades of cervical tissues derived from pre-
cancer (diagnosed and categorized by cytology as LSIL
and HSIL) and cancer lesions that represent natural his-
tory of HPV-induced cervical carcinogenesis. Concur-
rently, we examined the status of their HPV infection
(genotypes and HPVE6) and level of downstream targets
of STAT3 (MMP-2 and MMP-9) and miR-21 (TIMP-3
and PTEN).Materials and method
Cell lines and clinical specimens
Cervical cancer cell lines C33a (HPV-negative), CaSki
and SiHa (HPV16-positive) and HeLa (HPV18-positive)
were procured from ATCC and were maintained in pre-
scribed culture conditions. A total of 102 fresh cervical
tissue biopsies were collected comprising 56 malignant;
23 premalignant and 23 non-malignant control tissues
(comprising 3 normal and 20 tissues with cervicitis)
prior to any chemo/radio therapy from the Cancer
Clinic, Gynae OPDs of Lok Nayak Hospital and Guru
Teg Bahadur Hospital, Delhi, India respectively. Written
informed consent and clinico-epidemiological details
(Table 1) were taken from their clinical records. Each
tissue designated for molecular analysis was collected in
cold 1× phosphate buffer saline (PBS) and was immedi-
ately trifurcated to isolate and assayed DNA, RNA and
proteins by methods described below. All reagents used
in the study were of analytical or molecular biology
grade and procured from Sigma Aldrich (St Louis, MO,
USA) whereas primary and secondary antibodies and
ECL kit were purchased from Santa Cruz Biotechnology
(Santa Cruz Biotechnology Inc., Texas, USA) unless
specified.
Ethics, consent and permissions
Institutional Academic and Ethical Committee of Guru
Teg Bahadur Hospital approved the study vide sanction
no F.No. Mem.Sec./Ethical Comm/2011/3752-62 dated
16/03/2011. Written informed consent was obtained
from all the study subjects and was carried out in ac-
cordance with the principles of the Helsinki Declaration.
Isolation of DNA and diagnosis of HPV infection
Genomic DNA from cervical cancer cell lines and from
cervical cancer tissues was isolated from clinical samples
by the standard phenol-chloroform extraction procedure
[1, 36]. Briefly, the method involved fine mincing of
fresh tissue in cold 1X PBS with surgical blade in petrid-
ish on ice. The minced tissue material was collected in
1.5 ml tube and centrifuged at 3000 rpm for 5 min. after
centrifugation the PBS was discarded and minced tissue
material was then immediately suspended in 0.4 ml TE
(10 mM Tris–HCl + 1 mM EDTA, pH 8.0). To this sus-
pension 0.2 ml lysis buffer (3 % SDS in 2xTE, pH 8.0)
and Proteinase K (Roche, Basel, Germany) at 100 μg/ml
was added. The lysate was carefully mixed avoiding froth
formation and incubated overnight at 50 °C. Next day
equal volume (0.6 ml) of phenol (Merck Chemicals,
Darmstadt, Germany) (Tris-equilibrated, pH 8.0) was
added to the lysate and allowed to mix on an overhead
shaker for 15 min. This was followed by a centrifugation
at 6000 rpm for 10 min leading to the separation of two
distinct layers. The upper aqueous phase was carefully
Table 1 Clinico-pathological characteristics of cervical specimens and PCR-based analysis of their genomic DNA for HPV infection
and genotype analysis
Tissue type Characteristics Number of
samples










Normal/Control 23 1 (4.3 %) 1 (4.3 %) - - -
Cytolgically normal 3 - - - - -
Cervicitis 20 1 (5 %) 1 (5 %) - - -
Pre-cancer 23 14 (61 %) 12 (52 %) 1 (4.3 %) 0 -
LSIL 10 5 (50 %) 4 (40 %) 0 0 -
HSIL 13 9 (69 %) 8 (62 %) 1 (7.7 %) 0 -
Cancer Tissues 56 53 (95 %) 44 (79 %) 6 (11 %) 4 (7.1 %) 5 (9 %)
44a 39 (88.7 %) 33 (75 %) 6 (13.7 %) 1 (2.3 %) 5 (11.3 %)
Histopathological grading WDSCC 16 15 (94 %) 12 (75 %) 2 (13 %) 0 2 (13 %)
MDSCC 14 10 (71.4 %) 10 (71.4 %) 1 (7 %) 1 (7 %) 0
PDSCC 14 14 (100 %) 11 (79 %) 3 (21 %) 0 3 (21 %)
52a 48 (92 %) 42 (81 %) 5 (9.6 %) 4 (7.7 %) 5 (9.6 %)
Clinical stages Stage I 5 5 (100 %) 5 (100 %) 0 0 0
Stage II 17 15 (88 %) 14 (82 %) 2 (12 %) 1 (6 %) 1 (6 %)
Stage III 26 24 (92 %) 19 (73 %) 3 (11.5 %) 1 (4 %) 3 (11.5 %)
Stage IV 4 4 (100 %) 4 (100 %) 0 2 (50 %) 1 (25 %)
HPV human papillomavirus, SCC squamous cell carcinoma, LSIL low grade squamous intraepithelial lesions, HSIL high grade squamous intraepithelial lesions,
WDSCC well differentiated SCC, MDSCC moderately differentiated SCC, PDSCC poorly differentiated SCC. aHistopathological grading & clinical staging were
available for 44 and 52 samples respectively
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equal volume of phenol and CIA (chloroform: iso-amyl
alcohol [24:1]) (Qualigens fine chemicals, India) were
added, mixed on an overhead shaker and centrifuged as
in the previous step. The aqueous phase was transferred
to a fresh 1.5 ml tube. To this equal amount (0.6 ml) of
CIA was added, mixed and centrifuged. The upper aque-
ous layer was collected and DNA was precipitated over-
night at −20 °C. Following additions of 1/10th volume of
chilled 3 M sodium acetate (pH 5.2) and 2.5 volumes of
chilled absolute ethanol (Merck Chemicals, Darmstadt,
Germany), the precipitated DNA was precipitated out in
a micro centrifuge tube and washed in 70 % ethanol for
removal of traces of salt. It was finally centrifuged at
12,000 rpm for 5 min at room temperature to obtain a
pellet of DNA which was vacuum dried and re-suspendedTable 2 List of primers used for HPV infection, HPV typing, STAT3 RT
Primers Amplicon size Primer sequence
MY09/MY11 β-Globin 450 bp 268 bp 5’- GCM CAG GGW CA
W= A or T, Y = C or T a
5’- CAA CTT CAT CCA C
HPV16 217 bp 5’- AAG GCC AAC TAA
HPV18 322 bp 5’- ACC TTA ATG AAA
STAT3 RT 318 bp 5’-TTGCCAGTTGTGGTG
GAPDH RT 322 bp 5’-TGGATATTGTTGCCA
aList of primers and probes for PGMY reverse line blot-based comprehensive genoty
manual (First Edition; 2010)in 1xTE (pH 8.3), quantitated by UV spectrophotometry
and stored at −20 °C. HPV diagnosis was performed by
using a pair of consensus degenerate primers (MY09 and
MY11) (Table 2). PCR was performed in a 25 μl reaction
mixture containing 100 ng DNA, 10 mM Tris–HCl
(pH 8.4), 50 mM KCl, 1.5 mM MgCl2, 125 mM of each
dNTPs (MBI fermentas, Ontario, Canada), 5pmol of
oligonucleotide primers and 0.5U Taq DNA polymerase.
The temperature profile used for amplification constituted
an initial denaturation at 95 °C for 4 min followed by
30 cycles of denaturation at 95 °C for 30 s, annealing at
55 °C for 30 s and extension at 72 °C for 1 min, which was
extended for 5 min at the final cycle. HPV positive sam-
ples were subjected to comprehensive HPV genotyping by
PGMY-Reverse Line Blot which can detect about 32 HPV
types including all high-risk and low-risk types [37].PCR and quality control of RNAa
T AAY AAT GG -3’ 5’- CGT CCM ARR GGA WAC TGA -3’ Where M = A or C,
nd R = A or G 5’- GAA GAG CCA AGG ACA GGT AC-3’
GT TAC ACC-3’
ATG TCA C -3’ 5’- CTG CTT TTA TAC TAA CCG G -3’
AAC CAC GA -3’ 5’- CGT CGT TTA GAG TGG TTC GTG -3’
ATC-3’ 5’-GAACCCAGAAGGAGAAGC-3’
TCA ATGACC-3’ 5’-GATGGCATGGACTGTGGTCATG-3’
ping and the methodology can be obtained through WHO HPV laboratory
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type-specific PCRs as described earlier [1]. Beta-globin
amplification was done as internal control. Custom-
synthesized, HPLC-purified primers were procured from
M/s Microsynth (Germany) or M/s Eurogentec (Belgium).Isolation of total RNA and amplification of microRNAs by
real time-PCR (RT-PCR)
Total RNA from cell lines and clinical samples was ex-
tracted using mirVana miRNA isolation kit (Ambion,
Austin, USA) as per the manufacturer’s instructions.
Briefly, the method involves first to lyse the sample in a
denaturing lysis solution which stabilizes RNA and inac-
tivates RNases. The lysate is then extracted once with
Acid-Phenol: Chloroform which removes most of the
other cellular components, leaving a semi-pure RNA
sample. This is further purified over a glass-fiber filter.
microRNAs expression was checked by using mirVana
qRT-PCR kit and miR-21 and let-7a specific primers
(Ambion, Austin, USA) as per the kit protocol (Table 3).
First RT PCR was performed in a 10 μl reaction mixture
containing 20 ng RNA, 1X mirVana RT buffer, 1X mir-
Vana RT primer and ArrayScript enzyme mix. The
temperature profile used for amplification constituted an
initial incubation at 37 °C for 30 min followed by 10 min
incubation at 95 °C to inactivate the ArrayScript. Then
real time PCR was performed in a 10 μl reaction mixture
using 2 μl of the cDNA prepared in previous reaction,
SYBR Green and mirVana PCR Primers. The temperature
profile used for amplification constituted an initial de-
naturation at 95 °C for 3 min followed by 40 cycles of de-
naturation at 95 °C for 15 s and annealing at 60 °C for
30 s. PCR was performed using BioRad iCycler real-time
PCR (BioRad, USA). U6 RNA (Ambion, Austin, USA) was
used for normalization. Data were expressed as fold
change (2-ΔΔCt) with respect to pooled reference micro-
RNA prepared from equal amount of 3 non-malignant











The capital letters indicate universal primers sequence of miRNAs for RT and forwar
interest which binds to the miRNA. The amplicon size for each miR is 90 bpmiR expression analysis were procured from Dharmacon,
USA.Isolation of total proteins from cervical cell lines and
tissues and immunoblotting
Total proteins from cervical cancer cell lines and cer-
vical tissue biopsies were prepared by the method
described previously [38]. Briefly, the minced tissue ma-
terial or different cell lines (2 × 106 cells) was centrifuged
at 4,000 rpm at 4 °C to wash off 1x PBS solution. For
preparation of total proteins, the pellet was resuspended
in lysis buffer [20 mM Tris (pH 7.4), 250 mM NaCl,
2 mM EDTA (pH 8.0), 0.1 % Triton X-100, 0.01 mg/ml
aprotinin, 0.005 mg/ml leupeptin, 0.4 mM PMSF, and
4 mM Na3VO4]. Lysates were spun at 14,000 rpm for
10 min to remove insoluble material. The concentration
of proteins was determined by spectrophotometric method
using Bradford reagent (Biorad, Hercules, CA, USA) as
per protocol provide by the manufacturer and proteins
were stored in aliquots at −80 °C till further use. Total
cellular proteins (50 μg/lane) were separated in 8–12 %
polyacrylamide gel and electrotransferred on PVDF mem-
brane (Millipore Corp, USA). The membrane was first
probed with primary antibody. These blots were washed,
incubated with HRP-anti-mouse IgG secondary antibodies
and visualized by Luminol detection kit (Santa Cruz Bio-
tech) and by exposing the blot to KODAK X-Omat films
(Kodak India). The membranes were reprobed for β-actin
expression as an internal control. The quantitative densi-
tometric analysis of the bands was performed using Alpha
Ease FC version 4.1.0 (Alpha Innotech Corporation, IL).
Normalized fold difference in expression of STAT3,
pSTAT3 (Y705), HPV16 E6, MMP-2, MMP-9, PTEN and
TIMP-3 in each sample was determined by densitometric
analysis of each band in comparison to pooled normal
sample which was used as control and normalized for in-
put by using β-actin bands. The working dilution of all pri-











d primer of each miR while small letters sequence is specific for the miRNA of
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1:5000 and for secondary antibody it was 1:10,000.
Reverse transcription-PCR for STAT3 mRNA expression
Total RNA isolated by mirVana miRNA isolation kit
was subjected to reverse transcription using Omniscript
RT-PCR kit (Qiagen, Hilden, Germany) to prepare the
cDNA as per manufacturer’s instructions. Amplification
of STAT3 and GAPDH transcripts from the cDNAs was
performed as per routine laboratory procedure [1]. Nor-
malized fold difference in expression of STAT3 tran-
scripts in each sample was determined by densitometric
analysis of the band in comparison to respective band
in normal. Input was normalized by comparing respect-
ive GAPDH bands in normal and test lanes.
Statistical analysis
Quantitative data was described as mean ± standard error
(SE). Kruskal-Wallis test was done to check the significant
mean difference. Mann–Whitney test was employed to
compare the significant mean difference of microRNAs
expression correlation between two groups. p value <0.05
was considered significant. SPSS software (version 16.0)
was used for all statistical calculations.
Results
Established cervical cancer cell lines (C33a, SiHa, CaSki,
HeLa) and cervical biopsies comprising 23 pre-cancer,
56 cancer lesions and 23 control tissues were examined
for presence of HPV infection and their genotypes, the
expression level of miR-21, let-7a, STAT3 and pSTAT3
(Y705) in each specimen. Clinicopathological character-
istics of specimen and their status of HPV infection is
presented in Table 1. PCR-based detection revealed HPV
infection in 14 out of 23 cases (61 %) of pre-cancer le-
sions and 53 out of 56 cases (95 %) of cancer lesions
(Table 1). Among these, 12 out of 23 (52 %) pre-cancer
and 44 out of 56 (79 %) cancer cases were found to con-
tain HPV16 infection, whereas, only 6 (11 %) cancer
cases showed HPV18 infection. Cytological as well as mo-
lecular evaluation of control tissues from non-malignant
cervix revealed 3 cytological normal HPV negative tissues
whereas 20 tissues showed cytological changes resembling
cervicitis of which one was found HPV16-positive.
miR-21 and let-7a expression in cervical cancer cell lines
and tissue biopsies
Total RNA isolated from cervical cancer cell lines and
tissues was subjected to miR-specific qRT-PCR for the
analysis of miRNAs expression. RNA from C33a cells
and pooled RNA from normal cervical tissues were used
as control for semi-quantitative analysis of miRs expres-
sion in cell lines and tumor tissues, respectively. Variable
level of miR-21 and let-7a were detected among differentcervical cancer cell lines irrespective of their type of
HPV infection (Fig. 1a). In comparison to HPV-negative
C33a cells, HPV-positive SiHa, Caski and HeLa cells
showed high level of miR-21. On the other hand, let-7a
expression was low in HPV-positive cell lines. miRs
expression in normal/control tissues that passed for
amplification of internal control U6 (15/23) was uniform
except 5 outlier cases (3 for miR-21 and 2 for let-7a) and
resembled to pooled reference Additional file 1: Figure
S1A. Further examination revealed an overexpressed
miR-21 in pre-cancer and cervical cancer lesions and its
level increased from LSIL to HSIL. Level of miR-21 was
higher among tumor tissues from cancer lesions. In con-
trast, low level of let-7a was detected in cancer tissues
compared to the let-7a in pre-cancer and normal control
tissues. Among all tissue types, a characteristically high
level of let-7a was detected particularly in pre-cancer le-
sions (Fig. 1b & c).
Further, miR expression level was examined in tumor
tissues of different clinical stages and histopathological
grades. Clinical staging was available for 52 out of 56
cancer cases and histopathological grades were available
for 44 cancer lesions. Analysis revealed that despite vari-
ability, miR-21 level was distinctively high in advanced
cervical cancer lesions and the increase was progressive
with increase in the severity of the clinical manifestation
of cancer lesions in cervical cancer cases (Fig. 1d). As
the cervical lesions progressed from early stage I to ad-
vanced stage IV, let-7a showed a reciprocal kinetics.
Similarly, when miR level were examined in relation to
their respective histopathological grades, miR-21 level
did show only a marginal difference in well differentiated
squamous cell carcinoma (WDSCC) and poorly differen-
tiated squamous cell carcinoma (PDSCC), whereas its
level were significantly higher in high grade PDSCC le-
sions. Higher level of miR-21 was accompanied with low
level of let-7a in tissues of PDSCC lesions (Fig. 1e).
Association of STAT3 and pSTAT3 (Y705) with miR-21 and
let-7a level in cervical cancer
We examined association of miR level with expression
of total STAT3 and activated STAT3 which is phosphory-
lated at Y705 residue. Our earlier studies have confirmed
that pSTAT3 and STAT3 detected by immunoblotting are
transcriptionally active in cervical lesions and cervical can-
cer cells lines [1, 6]. Immunoblot analysis of cellular pro-
teins revealed constitutively active STAT3 expression in
all cervical cancer cell lines although the degree of expres-
sion was variable (Fig. 2a). In contrast to HPV-negative
C33a cells, all HPV-positive cells had higher expressions
of STAT3 as well as activated form of STAT3 (pSTAT3).
Immunoblotting for STAT3 and pSTAT3(Y705) could
be performed only in 70 out of 79 cases which revealed
a concordant increase in STAT3 and pSTAT3 level in
Fig. 1 (See legend on next page.)
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Fig. 1 Expression levels of miR-21 and let-7a in cervical cancer cells. a & b. Representative photograph showing specific amplification of
miR-21 and let-7a in quantitative real-time RT-PCR (qRT-PCR) of total RNA isolated from cervical cancer lines, C33a (HPV-), SiHa & CaSki (HPV16+)
and HeLa (HPV18+) (a); or from cervical tissues of normal (N), low grade squamous intra-epithelial lesion (LSIL), high grade SIL (HSIL) and cervical
cancer tissues (C1, C2) (b). Amplification of U6 RNA was performed as internal control for input RNA. miR fold change was calculated w.r.t. C33a in
case of cell lines or reference pooled RNA from normal tissues. Marker, ΦX174 Hae III-digested molecular weight marker; N, PCR negative control.
c. Cumulative data showing mean ± S.E. of fold change expression of miR-21 and let-7a in tumor tissues of pre-cancer and cancer lesions.
d & e. Distribution of miR-21 and let-7a expression in cancer tissues of different clinical stages (d) or in different histopathological grades (e) data
showing mean ± S.E. of fold change expression of miR-21 and let-7a in tumor tissues examined in 3 independent experiments. *p value <0.05;
**p value <0.01; ***p value <0.001. Note: The fold change being reflected in a & b may not corroborate with c, d & e as they are end products of
the qRT-PCR run
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expressed in these lesions was predominantly phosphor-
ylated. STAT3 and pSTAT3 level were evaluated densi-
tometrically and examined in association with level of
miR-21 and let-7a in corresponding clinical samples
(Fig. 2b). Based on the level of their expression and
the median value, cervical tissues were classified as
having either low or high level of STAT3/pSTAT3 ex-
pression in each disease group and their miR level
were evaluated accordingly (Fig. 2c & d). miR-21 level
were consistently higher in tissues which expressed
high level of STAT3 or pSTAT3 but this correlationFig. 2 Association of miR-21 and let-7a with STAT3 expression and activati
STAT3 and pSTAT3 (Y705) in cervical cancer cell lines (a) and in cervical tiss
and cervical tissues were immunoblotted for STAT3, pSTAT3 (Y705) and β-a
represent relative difference in levels of indicated proteins w.r.t. normal. No
tissue type was determined by densitometry as described in Methods in 3
(d) levels (Mean ± SE) in cervical tissues from pre-cancer and cancer lesions
were broadly classified into low or high STAT3/pSTAT3 based on median fo
disease group. STAT3 median values were LSIL – 0.97; HSIL – 1.27; Cancer –
1.51. *p value <0.05; **p value <0.01; ***p value <0.001was significant only in HSIL and cancer tissues. Op-
posite to this, let-7a level was significantly lower in
cancer tissues which expressed high level of STAT3/
pSTAT3 expression (Additional file 1: Figure S2A).
This trend was also observed in pre-cancer tissues but
relation was statistically insignificant. Further investiga-
tion of STAT3-miR correlation in tissues of different
histopathological grades revealed a similar trend of in-
creasing miR-21 along with higher STAT3/pSTAT3
level in PDSCC and concomitant decline in let-7a level
(Additional file 1: Figure S2b) but the distribution was
not statistically significant.on. a & b. Representative immunoblots showing expression of total
ues (b). Total cellular proteins (50 μg) isolated from indicated cell lines
ctin expression by respective antibodies. Values below each blot
rmalized fold difference in expression of STAT3/pSTAT3 band in each
independent experiments. c & d. Distribution of miR-21 (c) and let-7a
with corresponding STAT3/pSTAT3 protein levels. STAT3/pSTAT3 levels
ld difference in levels of expression of respective protein in each
2.1. pSTAT3 median values were LSIL – 0.68; HSIL – 1.06; Cancer –
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that varied with level of oncogene E6
In order to explore any potential correlation of miR-21
and let-7a with level of viral oncoproteins, we exam-
ined and quantitated relative level of E6 expression in
HPV16-positive lesion. Antibody used in the study spe-
cifically recognized HPV16 E6 and had only weak
binding to HPV18 E6 (Fig. 3a). Both the cervical can-
cer cells lines, SiHa and CaSki expressed prominent E6
level. Therefore, SiHa cells were used as reference in
quantitation of relative E6 level in tumor tissues (Fig. 3b).
Despite HPV16 positivity, we observed that level of
E6 were much lower in total cellular proteins of all
HPV16-positive LSIL and HSIL than cancer tissues.
Analysis of miR-21 level with respect to expression of
E6 in cervical lesions revealed higher level of miR-21
in high E6 expressing lesions irrespective of the tissue
type (Fig. 3c). Similarly, higher level of E6 were accom-
panied by lower level of let-7a in spite of the fact that
let-7a was overexpressed in LSIL and HSIL type of tis-
sues (Fig. 3d).Fig. 3 Association of miR-21 and let-7a with HPV16 E6 expression. a & b. R
cervical cancer cell lines (a) and biopsy tissues (b). β-actin levels were used
band in each tissue type was determined by densitometry as described in
SE) in HPV16-positive cervical tissues from pre-cancer and cancer lesions w
broadly classified into low or high groups based on median fold difference in
was measured w.r.t. E6 levels in SiHa cells which were used as reference. HPV
1.94. *p value <0.05; **p value <0.01; ***p value <0.001Expression of downstream targets of STAT3 and their
correlation with miR-21 expression in cervical tissues
As a direct examination of correlation between STAT3-
mediated upregulation of miR-21 transcription was not
feasible in tumor tissues, we therefore measured level of
two important mediators MMP-2 and MMP-9 that are
transcriptionally regulated by STAT3. Expression of
these proteins was detectable but was highly variable
among different cell lines (Fig. 4a). MMP-2 and MMP-9
were overexpressed particularly in tissues derived from
HSIL and cancer lesions (Fig. 4b). In the subsequent
study, we checked the correlation of MMP-2 and MMP-
9 expression with miR-21 level. Our immunoblotting
data of pre-cancer [13] and cancer [38] tissues out of 79
cases in relation to miR-21 level revealed a consistent
overexpression of MMP-2 and MMP-9 with high level
of miR-21 in all tissue types but this correlation was sta-
tistically significant only in cancer tissues (Fig. 4c & d).
Next, we examined the level of PTEN, and TIMP-3 to
assess potential regulatory effect of miR-21 on expression
of its target in cervical tumors. Initial immunoblottingepresentative immunoblots showing levels of HPV16 E6 in indicated
as input control. Normalized fold difference in expression of HPV16 E6
Methods. c & d. Distribution of miR-21 (c) and let-7a (d) levels (Mean ±
ith corresponding E6 protein levels. Relative normalized E6 levels were
HPV16 E6 levels in each disease group. Fold change in E6 expression
16 E6 protein level median values were LSIL – 0.91; HSIL – 0.98; Cancer –
Fig. 4 (See legend on next page.)
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Fig. 4 Association of miR-21 levels with STAT3 downstream targets. a & b. Representative immunoblots showing expression of MMP-2, MMP-9,
PTEN and TIMP-3 in indicated cervical cancer cell lines (a, e) and cervical tissue biopsies (b, f). Total cellular proteins (50 μg/lane) isolated from
cervical cancer cell lines and tissues immunoblotted for MMP-2, MMP-9, PTEN and TIMP-3 expression, blots were subsequently stripped and
reprobed with β-actin which was used as input control. Normalized fold difference in expression of the bands in each tissue type was determined
by densitometry as described in Methods in 3 independent experiments. c, d, g & h. Distribution of miR-21 levels (Mean ± SE) in cervical tissues
from pre-cancer and cancer lesions with corresponding MMP-2, MMP-9, PTEN and TIMP-3 protein levels. Relative normalized protein levels were
broadly classified into low or high groups based on median fold difference in respective protein levels in each disease group w.r.t. normal pooled
control sample. MMP-2 protein level median values were LSIL – 1.02; HSIL – 1.4; Cancer – 1.56. MMP-9 protein level median values were LSIL –
0.98; HSIL – 1.15; Cancer – 1.44. PTEN protein level median values were LSIL – 1.62; HSIL – 1.17; Cancer – 0.67. TIMP-3 protein level median values
were LSIL – 1.18; HSIL – 1.02; Cancer – 0.9. *p value <0.05; ***p value <0.001
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TIMP-3 were conducted in HPV-positive cervical cancer
cell lines SiHa, HeLa and Caski which showed low but de-
tectable level of these proteins (Fig. 4e). On the other
hand, C33a cells expressed both of these proteins at a
comparatively higher level. A high level of both of these
proteins was detected in normal cervical tissues which
was found gradually diminished in tissues from pre-cancer
and cancer lesions (Fig. 4f). Analysis of tumor tissues for
expression of these proteins along with miR-21 level re-
vealed low level of PTEN and TIMP-3 in tissues where
level of miR-21 were comparatively high (Fig. 4g & h).
These correlations were significant particularly in tissues
from HSIL and cancer lesions.
Inverse correlation of let-7a level with STAT3 transcripts
in cervical tissues
In the next part of the investigation, we examined effects
of let-7a on STAT3 transcripts by performing STAT3-
specific RT-PCR on cDNA obtained from different tumor
tissues and measured the fold change in expression ofFig. 5 let-7a levels are inversely correlated with STAT3 transcripts. a. Repres
in cDNA of indicated tissue types by RT-PCR (upper panel). GAPDH RT-PCR
Hae III-digested molecular weight marker; Positive control (P), Negative con
Normalized fold difference in expression of the bands in each tissue type was
experiments. b. Distribution of let-7a levels (Mean ± SE) in cervical tissues from
levels. Relative normalized STAT3 mRNA levels were broadly classified into low
in each disease group. STAT3 mRNA median values were LSIL – 0.65; HSIL – 0STAT3 with respect to normal control (Fig. 5a). STAT3
transcripts were evaluated in 52 out of 79 pre-cancer and
cancer cases. HPV-positive HSIL and cervical cancer le-
sions expressed high level of STAT3 transcripts in con-
cordance with the protein expression as observed earlier
(Fig. 5a). The elevated level of STAT3 transcripts were ac-
companied by a low level of let-7a in cancer cells (Fig. 5b).
On the contrary, both LSIL and HSIL in general expressed
high let-7a, which was accompanied by low level of
STAT3 transcripts. Moreover, differential analysis of let-7a
in pre-cancer lesions showed a consistent lower level,
which expressed relatively high level of STAT3 transcripts.
Discussion
Analysis of cervical cancer cell lines and tumor tissues
revealed a differential expression of two key microRNAs,
miR-21 and let-7a, that correlated with aberrant STAT3
expression and activity. The expression of miR-21 was
significantly higher while let-7a showed a low level in
cervical cancer tissues. While miR-21 showed direct as-
sociation, let-7a expression was inversely related to theentative photograph showing amplification of STAT3 transcript levels
of respective cDNA was used as input control (lower panel). M: ΦX 174
trol (N), Normal, LSIL, HSIL and Cancer (C1, C2) cervical tissue biopsies.
determined by densitometry as described in Methods in 3 independent
pre-cancer and cancer lesions with corresponding STAT3 transcript
or high groups based on median fold difference in STAT3 mRNA levels
.8; Cancer – 1.2. *p value <0.05; ***p value <0.001
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HPV-positive cervical cancer lesions. Interestingly, such
a reciprocal kinetics was not observed for let-7a particu-
larly in pre-cancer lesions. Typically lesions with LSIL
and HSIL cytology overexpressed let-7a. In HPV-positive
lesions, miR-21 level corresponded to the level of onco-
protein E6. On the contrary, let-7a level was consistently
low in lesions expressing high levels of E6. Low let-7a
corresponded with higher STAT3 at mRNA level. Over-
expression of miR-21 was found associated with elevated
level of other STAT3 regulated gene products MMP-2
and MMP-9 and decreased level of its known target
gene products, PTEN and TIMP-3 that negatively regu-
late STAT3 signaling and its downstream effect via
MMPs, respectively.
As a downstream regulatory gene product of STAT3
signaling, miR-21 showed an increased expression with
disease progression and severity of the disease in HPV16-
positive pre-cancer and cancer lesions. Oncogenic role of
aberrantly expressed miR-21 have been proposed in cer-
vical carcinogenesis [21–25]. However, its expression was
highly variable within the cervical tissues. Our recent ob-
servations based on functional silencing of STAT3 signal-
ing in cervical cancer cells by STAT3-specific siRNA or by
using specific inhibitors like curcumin or Stattic resulted
in loss of cellular miR-21 pool [15]. Clinical data obtained
from present investigation along with support from our
earlier mechanistic study in an in vitro experimental
system strongly suggest transcriptional upregulation of
miR-21 through constitutive activity of STAT3 present in
cervical cancer cells [1, 3, 4, 6].Fig. 6 Schematic representation of miR-STAT3 regulatory loop during cervi
the mechanistic experimental validation of these observations recently pub
URR – upstream regulatory regionContrary to miR-21, let-7a had high expression level
in tissues from pre-cancer lesions but was low or absent
in clinically-advanced cancer lesions. Presence of let-7a in
copious amounts in HSIL and absence in malignant le-
sions indicates to a major alteration at genetic or epigen-
etic level that could be essential for malignant switching
and for maintaining the sustained level of STAT3 in ma-
lignant cells. However, further studies are needed to
understand malignant switching with a particular refer-
ence to let-7a. Nevertheless, it can be speculated that
oncoprotein E6 may directly or indirectly influence cellu-
lar let-7a levels which was not only consistently found
negatively correlated to the level of E6 in all spectrum of
clinical samples but was found to reappear if E6 was si-
lenced in cervical cells in cultures [15]. Incidentally, silen-
cing E6 has been associated with loss of STAT3 both at
mRNA and protein level [1, 6, 15]. Further, transient
transfection of let-7a mimics or let-7a precursor which are
stable biologically active molecules, directly and effectively
silenced the STAT3 expression [15, 26].
Further, we analyzed two other STAT3-controlled gene
products, MMP-2 and MMP-9. We observed an upregu-
lated expression of these proteins in cervical cancer cell
lines and cancer lesions. Their level corresponded with
miR-21. Active STAT3 is known to modulate the expres-
sion and activity for both MMPs and their inhibitors,
TIMPs [39–42]. We also found reduced expression of
TIMP-3 particularly in miR-21 overexpressed cancer le-
sions. Recently, miR-21 has been shown to contribute to
invasiveness by downregulation of MMP inhibitor, TIMP-
3 [43]. Reduced TIMP-3 relieves the inhibition on MMP-2cal carcinogenesis. Based on clinical finding of the present study and
lished by us [Shishodia et al. (15)]. Key: S3BS –STAT3 binding site,
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leads to the invasive behavior of malignant cells [44].
TIMP-3 contains a putative consensus miR-21 binding
site that plays a key role in regulating the TIMP-3 tran-
scripts by miR-21 [44]. These observations collectively in-
dicate that aberrant STAT3-mediated events include
upregulation of MMPs expression and activity, which
could partly be facilitated through activation of miR-21 via
suppression of TIMP-3.
In addition to TIMP-3, PTEN which is another mo-
lecular target of miR-21 was also found specifically
downregulated in miR-21 overexpressing lesions. miR-21
targets PTEN gene through a binding site on 3’-UTR
[18]. Low level of PTEN has been reported in cervical
cancer [45–47]. Among negative regulators of STAT3,
PTEN is responsible for its dephosphorylation and con-
trols overall level of transcriptionally-active phospho
(Y705) form of STAT3 [48]. Silencing of miR-21 in cer-
vical cancer cells by miR-21-specific inhibitor or silen-
cing of HPV E6 resulted in intracellular accumulation of
PTEN and a corresponding loss of phospholylated form
of STAT3 [15]. Thus, these observations collectively sug-
gest a potential role of miR-21 in maintaining high levels
of aberrantly activated STAT3 in cervical cancer cells by
targeting its negative regulator, PTEN.
Overall, present study suggests higher miR-21 and re-
duced let-7a expression level are strongly associated with
aberrant expression and activation of STAT3 in cervical
carcinogenesis and reflects a close link with high risk
HPV16 infection having a higher expression of E6 onco-
protein. These clinical findings support our previous re-
port [15] demonstrating experimentally the presence of
a functional regulatory loop during cervical carcinogenesis
(Fig. 6). Present study, therefore, advocates an operational
microRNA-mediated loop that assists constitutively active
STAT3 signaling during cervical cancer progression. miR-
21 and let-7a along with STAT3 collectively form clinically
useful set of biomarkers to identify invasive lesions that
may be targeted by STAT3 pathway-specific inhibitors for
effective management of pre-invasive and invasive cervical
cancer lesions.Additional file
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